Pfizer has terminated development of its RSV treatment candidate sisunatovir, a viral inhibitor picked up in its up to $525 ...

Data submitted to the FDA by Stealth BioTherapeutics for its ultra-rare disease drug likely aren’t sufficient for an approval ...

A gene therapy pioneer thinks he has a solution to the field’s struggle to commercialize breakthrough cures: Go global. Jim ...

A trade group for large compounding pharmacies sued the FDA over its move to take Eli Lilly’s blockbuster GLP-1 drug off its ...

City Therapeutics has launched with $135 million and Alnylam’s former CEO leading the charge as it develops a pipeline of ...

A protein called alpha-synuclein that accumulates and ravages the brains of some people with Parkinson’s disease is the ...

Pfizer's former CEO and CFO relayed proposals from activist investor Starboard Value to several members of the company's ...

Sage Therapeutics is reeling from another mid-stage setback as its investigational medicine dalzanemdor has missed the mark ...

Nearly eight years after securing a historic first approval for a spinal muscular atrophy drug, Biogen is seeking to launch a ...

As Merck builds out its immunology research lab in London, it's partnering with a local biotech startup that has remained ...

Black Diamond Therapeutics is cutting an unspecified number of workers, including several executives, and making changes to ...

As it works to rebuild from an earlier gene therapy setback, Astellas is doubling down on the one-and-done modality in a new ...